Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

NANEMIAR Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA

Coordinator
Fundacion Para La Formacion E Investigacion Sanitarias De La Region De Murcia, Spain
Runs
1 October 2023 to 28 February 2027
Status
Running
EU funding
€2.7m
Total cost
€2.7m
Partners
4 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101080156

What the project is doing

In the project's own words, from its summary on CORDIS.

Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and low toxicity. Compared to DNA-based gene therapy, mRNA has significant advantages including higher intrinsic safety (non-integrating), lower cost of development, and less stringent regulatory requirements for clinical approval. In the NANEMIAR project, we take advantage of these benefits to kill 2 birds with 1 stone: first, we develop a first-of-its-kind nanomedicine for congenital anemia, a group of rare, inherited blood disorders characterized by ineffective red blood cell production.

Our proposed bone marrow-targeted mRNA-based therapy contributes to the first Horizon Europe strategic plan (2021-2024) for new and advanced therapies for non-communicable diseases and is expected to be a vast improvement over current treatment options in terms of efficacy and safety. Second, we provide critical knowledge on targeted non-viral polynucleotide delivery, with a platform that can be exploited for next-generation cell and gene therapy in a broader context.

To achieve this, our consortium combines the unique cell-targeting and mRNA knowledge from the Dutch Biotech Mercurna with two excellent research partners (from Spain and France) who have demonstrated expertise in the field of anemia. By focusing on the well-recognized rare disease model, beta-thalassemia, and combining an established mouse model, patient material, and previous drug development experience we build a convincing case to treat congenital anemia.

Topics

Who is involved

OrganisationCityCountryRole
Fundacion Para La Formacion E Investigacion Sanitarias De La Region De MurciaMurciaSpainCoordinator
Servicio Murciano De SaludMurciaSpainThird party
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Mercurna BVNijmegenNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI